Releases
VTVT
24.74
+2.44%
0.59
  • All
  • Financials
  • Insiders
More
Webull provides the latest Vtv Therapeutics (VTVT) stock and general news. This information may help you make smarter investment decisions.
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes HPP593, Nrf2/Bach1 Modulator Program, Azeliragon and HPP3033.